Consensus Spero Therapeutics, Inc.

Stocks

SPRO

US84833T1034

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 28/08/2026 BST			5-day change	1st Jan Change
1.200 ^USD	-0.83%		-1.64%	-48.50%

08-12	Spero Therapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
08-12	Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Spero Therapeutics, Inc.

Evolution of the Target Price: Spero Therapeutics, Inc.

Changes in Analyst Recommendations: Spero Therapeutics, Inc.

ddad3f7af71248ce592d72d92c766.nPI4ABnroqE1PfxmpcVBSatm5EWffz4U5p9N994zjWs.8JhfYlqk1PJsUZ8Q3KEjIZ4MqgSpHApYge91j7FQwCPennUzKZPPk0dIlw~6f2c7fd687d6d4750a2524942450f49f

Analysts' recommendations: Spero Therapeutics, Inc.

21/10/25	Spero Therapeutics, Inc. and Gsk plc Announces Efficacy and Safety Results of the Positive Pivot-Po Trial Evaluating Tebipenem Hbr	CI
20/12/24	Evercore ISI Downgrades Spero Therapeutics to In Line From Outperform, Price Target is $5	MT
18/11/24	TD Cowen Downgrades Spero Therapeutics to Hold From Buy	MT
06/08/24	TD Cowen Upgrades Spero Therapeutics to Buy From Hold	MT
14/08/23	HC Wainwright Adjusts Price Target on Spero Therapeutics to $7 From $6, Keeps Buy Rating	MT
26/09/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $6 From $7, Maintains Buy Rating	MT
22/09/22	Evercore ISI Upgrades Spero Therapeutics to Outperform From In-Line	MT
15/08/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $7 From $10, Keeps Buy Rating	MT
01/07/22	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	MT
23/05/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $10 from $37, Keeps Buy Rating	MT
20/05/22	Berenberg Bank Downgrades Spero Therapeutics to Hold From Buy, Adjusts Price Target to $2 From $44	MT
17/05/22	Cantor Fitzgerald Lowers Spero Therapeutics' Price Target to $5 From $27, Overweight Rating Kept	MT
04/05/22	Cowen Downgrades Spero Therapeutics to Market Perform From Outperform	MT
04/05/22	Evercore ISI Downgrades Spero Therapeutics to In-Line From Outperform, Adjusts Price Target to $2 From $40	MT
18/04/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $37 From $43, Maintains Buy Rating	MT
21/03/22	HC Wainwright Adjusts Spero Therapeutics' Price Target to $43 From $40, Keeps Buy Rating	MT
16/11/21	Berenberg Bank Adjusts Spero Therapeutics PT to $44 From $47, Maintains Buy Rating	MT
01/10/21	Spero Therapeutics : Oppenheimer Downgrades Spero Therapeutics to Perform from Outperform	MT
12/03/21	Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $20 From $21, Maintains Outperform Rating	MT
22/01/21	Spero Therapeutics : HC Wainwright Adjusts Spero Therapeutics' Price Target to $40 From $33, Keeps at Buy	MT
05/01/21	Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $21 From $19, Maintains Outperform Rating	MT
16/12/20	Spero Therapeutics : Berenberg Starts Spero Therapeutics at Buy With $47 Price Target	MT
23/11/20	Spero Therapeutics : HC Wainwright Adjusts Price Target on Spero Therapeutics to $33 From $28, Reiterates Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
SPERO THERAPEUTICS, INC.	-	-	-	+233.33%
WUXI APPTEC CO., LTD.				+16.85%
ARGENX SE				+9.86%
WUXI BIOLOGICS (CAYMAN) INC.				+10.81%
INSMED INCORPORATED				+68.87%
BIONTECH SE				+17.86%
PHARMAESSENTIA CORPORATION				-13.15%
GENMAB A/S				+12.58%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.				+20.2%
EXELIXIS, INC.				-2.66%
Average				+37.45%
Weighted average by Cap.				+16.39%